Precigen presents preclinical data for the next generation mesothelin ultracar-t® with intrinsic pd-1 blockade at the aacr annual meeting 2023

Germantown, md., april 17, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presents preclinical data for the next generation ultracar-t platform utilizing msln car from precigen's library of non-viral plasmids at the american association for cancer research (aacr) annual meeting 2023
PGEN Ratings Summary
PGEN Quant Ranking